Atlas Trials

Immunomic Therapeutics, Inc.

7 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Immunomic Therapeutics, Inc.

RecordFirmDate
Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary Immunogenicity of ITI-9001 in Japanese Patients With Japanese Red Cedar (JRC) Pollinosis (NCT07726147)Immunomic Therapeutics, Inc.2026-06-20
Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) (NCT05698199)Immunomic Therapeutics, Inc.2023-08-21
Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC) (NCT05422781)Immunomic Therapeutics, Inc.2022-06-13

Track Immunomic Therapeutics, Inc. automatically

Every clearance here is in the API, with alerts when new ones post.